Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 1—January 2023
Dispatch

COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USA

Michael E. DeWittComments to Author , Ashley H. Tjaden, David Herrington, John Schieffelin, Michael Gibbs, William S. Weintraub, John W. Sanders1, Sharon L. Edelstein1, and on behalf of the COVID-19 Community Research Partnership
Author affiliations: Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA (M.E. DeWitt, D. Herrington, J.W. Sanders); The George Washington University Milken Institute of Public Health, Rockville, Maryland, USA (A.H. Tjaden, S.L. Edelstein); Tulane School of Medicine, New Orleans, Louisiana, USA (J.S. Schieffelin); Atrium Health, Charlotte, North Carolina, USA (M.A. Gibbs); MedStar Health, Columbia, Maryland, USA (W.S. Weintraub); Georgetown University, Washington, DC, USA (W.S. Weintraub)

Main Article

Table 1

Overview of demographics and key characteristics of study population in the North Carolina COVID-19 Community Research Partnership study on COVID-19 reinfection, North Carolina, USA*

Characteristic Pre-Delta, n = 37,711 Delta, n = 24,664 Omicron, n = 19,189
Median age, y (IQR)
49 (37–62)
53 (41–64)
55 (43–65)
Sex
F 26,001 (69) 17,156 (70) 13,233 (69)
M
11,710 (31)
7,508 (30)
5,956 (31)
Race
Asian 727 (1.9) 404 (1.6) 296 (1.5)
Black or African American 2,122 (5.6) 1,205 (4.9) 870 (4.5)
White 32,946 (87) 21,985 (89) 17,218 (90)
Other
1,916 (5.1)
1,070 (4.3)
805 (4.2)
Ethnicity
Other 3,245 (8.6) 1,748 (7.1) 1,266 (6.6)
Hispanic or Latino 942 (2.5) 562 (2.3) 442 (2.3)
Mixed ethnicity 500 (1.3) 317 (1.3) 239 (1.2)
Not Hispanic/Latino
33,024 (88)
22,037 (89)
17,242 (90)
Healthcare worker
10,488 (28)
6,914 (28)
5,077 (26)
Site
Atrium 8,362 (22) 6,112 (25) 4,983 (26)
Campbell 744 (2.0) 450 (1.8) 259 (1.3)
New Hanover 716 (1.9) 540 (2.2) 0 (0)
Vidant 1,367 (3.6) 692 (2.8) 0 (0)
Wake Forest 23,475 (62) 14,628 (59) 12,122 (63)
Wake Med
3,047 (8.1)
2,242 (9.1)
1,825 (9.5)
Median no. days reporting during wave (IQR)
169 (62–326)
129 (56–167)
47 (22–57)
Vaccination status
Fully vaccinated by beginning of wave 1,149 (3.0) 21,772 (88) 18,092 (94)
Fully vaccinated by end of wave† 24,264 (64) 22,597 (92) 18,112 (94)
Boosted by beginning of wave‡ 0 122 (0.5) 14,595 (76)
Boosted by end of wave‡
6 (<0.1)
15,623 (63)
15,348 (80)
COVID-19 positive test§
1,908 (5.1)
1,472 (6.0)
2,090 (11)
Reinfection¶
8 (0.4)
43 (2.9)
132 (6.3)
Vaccine breakthrough infection
47 (2.5)
1,233 (84)
1,936 (93)
Booster breakthrough infection 0 360 (24) 1,444 (69)

*Values are no. (%) except as indicated. IQR, interquartile range. †>14 days after receipt of first dose if first dose is Johnson & Johnson/Janssen (https://www.jnj.com); >14 days after date of receipt of second dose if first dose is Pfizer-BioNTech (https://www.pfizer.com), Moderna (https://www.modernatx.com), other, or missing. ‡Self-reported receipt of a second dose >60 days following an initial Janssen vaccination or reported a third dose >60 days after the receipt of 2 doses of Pfizer/Moderna/other/missing. §Self-reported. ¶ Self-reported positive test (COVID-19 infection (sample by nasal swab, saliva or spit) >90 days after a prior positive test.

Main Article

1These senior authors contributed equally to this article.

Page created: December 09, 2022
Page updated: December 22, 2022
Page reviewed: December 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external